5.81
0.52%
+0.03
Angiodynamic Inc stock is currently priced at $5.81, with a 24-hour trading volume of 310.65K.
It has seen a +0.52% increased in the last 24 hours and a +7.59% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.78 pivot point. If it approaches the $5.85 resistance level, significant changes may occur.
Previous Close:
$5.78
Open:
$5.78
24h Volume:
310.65K
Market Cap:
$232.72M
Revenue:
$324.01M
Net Income/Loss:
$-192.37M
P/E Ratio:
36.31
EPS:
0.16
Net Cash Flow:
$-23.46M
1W Performance:
-7.19%
1M Performance:
+7.59%
6M Performance:
-6.29%
1Y Performance:
-29.92%
Angiodynamic Inc Stock (ANGO) Company Profile
Name
Angiodynamic Inc
Sector
Industry
Phone
518-795-1400
Address
14 Plaza Drive, Latham
Angiodynamic Inc Stock (ANGO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-17-23 | Downgrade | Raymond James | Strong Buy → Outperform |
Oct-15-21 | Upgrade | Canaccord Genuity | Hold → Buy |
Aug-20-21 | Initiated | Oppenheimer | Perform |
Nov-25-20 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
Apr-08-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Apr-01-19 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Apr-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-05-18 | Downgrade | Craig Hallum | Buy → Hold |
Apr-07-17 | Reiterated | Cantor Fitzgerald | Overweight |
Mar-30-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
Feb-08-17 | Initiated | Barclays | Equal Weight |
Nov-04-16 | Initiated | Cantor Fitzgerald | Buy |
Apr-08-16 | Resumed | Piper Jaffray | Neutral |
Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
Nov-10-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jul-24-15 | Initiated | KeyBanc Capital Mkts | Overweight |
Jun-19-14 | Upgrade | Canaccord Genuity | Hold → Buy |
Oct-09-12 | Reiterated | Canaccord Genuity | Hold |
Jun-25-12 | Downgrade | Canaccord Genuity | Buy → Hold |
Jul-15-11 | Upgrade | Canaccord Genuity | Hold → Buy |
Jul-15-11 | Upgrade | Stifel Nicolaus | Hold → Buy |
Jun-14-11 | Downgrade | Wedbush | Neutral → Underperform |
Sep-08-10 | Reiterated | Wedbush | Neutral |
View All
Angiodynamic Inc Stock (ANGO) Latest News
Insiders Buying Zumiez And 3 Other Stocks
Benzinga
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
Zacks Investment Research
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
Zacks Investment Research
AngioDynamics (ANGO) Settles Patent Litigations With BD
Zacks Investment Research
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
Zacks Investment Research
Angiodynamic Inc Stock (ANGO) Financials Data
Angiodynamic Inc (ANGO) Revenue 2024
ANGO reported a revenue (TTM) of $324.01 million for the quarter ending February 29, 2024, a -3.19% decline year-over-year.
Angiodynamic Inc (ANGO) Net Income 2024
ANGO net income (TTM) was -$192.37 million for the quarter ending February 29, 2024, a -416.55% decrease year-over-year.
Angiodynamic Inc (ANGO) Cash Flow 2024
ANGO recorded a free cash flow (TTM) of -$23.46 million for the quarter ending February 29, 2024, a -101.38% decrease year-over-year.
Angiodynamic Inc (ANGO) Earnings per Share 2024
ANGO earnings per share (TTM) was -$4.78 for the quarter ending February 29, 2024, a -408.51% decline year-over-year.
About Angiodynamic Inc
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. It also offers thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; and Asclera injection for treating uncomplicated spider and reticular veins of the lower extremities. Further, it provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation system; and radiofrequency ablation products for ablating solid cancerous or benign tumors. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Cap:
|
Volume (24h):